Search results
Results from the Go Local Guru Content Network
The beta-1 adrenergic receptor (β 1 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue.
Beta-1 adrenergic receptors are the primary receptor of the heart and, therefore, autoantibodies to these receptors have been tied to many different heart diseases. Autoantibodies to beta1-adrenergic receptors are linked to chronic heart failure.
There are two main groups of adrenoreceptors, α and β, with 9 subtypes in total: α receptors are subdivided into α 1 (a G q coupled receptor) and α 2 (a G i coupled receptor) [7] α 1 has 3 subtypes: α 1A, α 1B and α 1D [a] α 2 has 3 subtypes: α 2A, α 2B and α 2C. β receptors are subdivided into β 1, β 2 and β 3.
The cellphone-friendly website and "MYmta" app, currently in a beta test phase, show straphangers real-time subway, bus and commuter rail information that has been housed in separate apps.
Beta 1-adrenergic agonists, also known as Beta 1-adrenergic receptor agonists, are a class of drugs that bind selectively to the beta-1 adrenergic receptor. As a result, they act more selectively upon the heart. Beta-adrenoceptors typically bind to norepinephrine release by sympathetic adrenergic nerves and to circulating epinephrine.
Beta adrenergic agonists or beta agonists are medications that relax muscles of the airways, causing widening of the airways and resulting in easier breathing. They are a class of sympathomimetic agents, each acting upon the beta adrenoceptors.
This page was last edited on 1 December 2007, at 08:14 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply.
MYmta is a mobile application-based passenger information display system developed by the Metropolitan Transportation Authority (MTA) of New York City. A beta version of the app was launched on July 2, 2018, and as of June 2019 [update] is still undergoing beta testing .
Alpha-1 blockers (also called alpha-adrenergic blocking agents or alpha-1 antagonists) constitute a variety of drugs that block the effect of catecholamines on alpha-1-adrenergic receptors. They are mainly used to treat benign prostatic hyperplasia (BPH), hypertension and post-traumatic stress disorder. [1]
A beta version of MYmta was released to the general public in July of that year. In future versions of the MYmta app, the MTA planned to integrate the eTix functionality, as well as make it easier for Access-A-Ride customers to view when their vehicle will arrive at a certain point.